Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006; 91: 1596–1604.

    PubMed  Google Scholar 

  2. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  3. Deguchi K, Gilliland DG . Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 2002; 16: 740–744.

    Article  CAS  PubMed  Google Scholar 

  4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. 2008, International Agency for Research on Cancer (IARC): Lyon.

    Google Scholar 

  5. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC et al. RUNX1 gene mutation in primary myelodysplastic syndrome—the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405–414.

    Article  CAS  PubMed  Google Scholar 

  6. Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134: 302–306.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the coworkers in our laboratory for their excellent technical assistance, as well as all physicians for referring the sample material to our center.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F Dicker.

Ethics declarations

Competing interests

SS, WK, CH, TH own and are employed by the Munich Leukemia Laboratory (MLL) GmbH. NW, JS, TW and FD are employed by MLL GmbH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dicker, F., Haferlach, C., Sundermann, J. et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 24, 1528–1532 (2010). https://doi.org/10.1038/leu.2010.124

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.124

This article is cited by

Search

Quick links